Anika Therapeutics

Anika Therapeutics

Yahoo Finance • 22 days ago

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

Novartis NVS announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has issued a positive opinion recommending marketing authorization for an additional indication of its arthrit... Full story

Yahoo Finance • 28 days ago

Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study

Immunocore IMCR announced that it has achieved target enrollment of 540 patients in the phase III TEBE-AM study, which is evaluating its sole marketed drug, Kimmtrak (tebentafusp), in patients with second-line or later advanced melanoma.... Full story

Yahoo Finance • last month

Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder

Roche RHHBY announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking approval of Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).... Full story

Yahoo Finance • last month

Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall

Novartis AG NVS announced that the late-stage HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1) failed to meet the primary endpoint. Del-desiran is an investigational antibody oligonucleotide conjug... Full story

Yahoo Finance • last month

ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study

AbbVie ABBV reported positive top-line data from the phase III CERVINO study, evaluating its investigational pipeline candidate, etentamig, in certain patients with relapsed/refractory multiple myeloma (RRMM) who had received prior treatme... Full story

Yahoo Finance • last month

Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies

Novartis NVS announced positive top-line results from the late-stage REMODEL-1/-2 studies on remibrutinib in relapsing multiple sclerosis (RMS). Remibrutinib is a highly selective oral Bruton's tyrosine kinase (BTK) inhibitor that blocks... Full story

Yahoo Finance • last month

GSK to Advance mRNA Influenza Vaccine Into Phase III Development

GSK plc GSK announced that it plans to advance the mRNA-based seasonal influenza (flu) vaccine candidate into late-stage development. This advancement is supported by positive results from a phase II study, which showed that the company's... Full story

Yahoo Finance • last month

Axsome Begins Phase III Study on AXS-05 for Smoking Cessation

Axsome Therapeutics AXSM announced that it has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for the treatment of smoking cessation. The randomized, double-blind, placebo-controlled phase III SUMMIT study is desi... Full story

Yahoo Finance • last month

JAZZ Rises on Updated OS Results From Gastric Cancer Study

Jazz Pharmaceuticals JAZZ announced second interim top-line overall survival (OS) results from the phase III HERIZON-GEA-01 study, which evaluated different combination regimens involving its marketed drug, Ziihera (zanidatamab) as a first... Full story

Yahoo Finance • 2 months ago

Best Momentum Stocks to Buy for August 26th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 26: BrightSpring Health Services, Inc. BTSG: This home and community-based healthcare services platformhas a Zacks Rank #1 and... Full story

Yahoo Finance • 2 months ago

J&J's Imaavy Gets FDA Approval as the First Treatment for wAIHA

Johnson & Johnson JNJ announced that the FDA has approved Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients aged 12 years and above who are currently or have been previ... Full story

Yahoo Finance • 2 months ago

Anika (ANIK) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, July 29, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Stephen D. GriffinSenior Vice President, Chief Accounting Officer, and Treasurer - Ian W. McLeodExec... Full story

Yahoo Finance • 2 months ago

Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- American News GroupNews Commentary - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox® created... Full story

Yahoo Finance • 2 months ago

Anika projects 2026 adjusted EBITDA margin of 13% to 17% as it raises revenue growth outlook to 5% to 10%

Earnings Call Insights: Anika Therapeutics (ANIK) Q2 2026 MANAGEMENT VIEW * “The second quarter marked great progress in our efforts to build a stronger, more profitable Anika,” said (President, Principal Financial Officer, CEO & Direc... Full story

Yahoo Finance • 4 months ago

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced... Full story

Yahoo Finance • 5 months ago

Anika Therapeutics, Inc. Q1 2026 Earnings Call Summary

Anika Therapeutics, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Performance Drivers Commercial channel growth of 12% was driven by the continued momentum of the Integrity platform and strong international OA pain management perfo... Full story

Yahoo Finance • 5 months ago

Anika Reports First Quarter 2026 Financial Results

Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execution Operational transformation genera... Full story

Yahoo Finance • 6 months ago

Anika (ANIK) Q2 2025 Earnings Call Transcript

Image source: The Motley Fool. Date Wednesday, July 30, 2025 at 8:30 a.m. ET Call participants President and Chief Executive Officer — Cheryl Renee Blanchard, Ph.D. Executive Vice President, Chief Financial Officer and Chief Operating... Full story

Yahoo Finance • 6 months ago

Anika (ANIK) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. Date Thursday, Feb. 26, 2026 at 8:30 a.m. ET Call participants President and Chief Executive Officer — Stephen Griffin Senior Vice President, Chief Accounting Officer and Treasurer — Ian McLeod Need a qu... Full story

Yahoo Finance • 6 months ago

Telix Strengthens Board with Additional Director Appointments

MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, a... Full story